Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $40.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 403.78% from the stock’s current price.

CAPR has been the topic of a number of other research reports. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday. Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, September 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.00.

Capricor Therapeutics Trading Up 33.0 %

NASDAQ:CAPR traded up $1.97 during midday trading on Tuesday, hitting $7.94. 11,267,752 shares of the company traded hands, compared to its average volume of 414,013. The firm’s fifty day moving average is $4.39 and its 200-day moving average is $5.19. The firm has a market capitalization of $253.91 million, a P/E ratio of -9.09 and a beta of 3.92. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $9.24.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The business had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. On average, research analysts expect that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics in the first quarter worth about $40,000. Main Street Financial Solutions LLC increased its position in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares in the last quarter. Rhumbline Advisers purchased a new stake in Capricor Therapeutics in the 2nd quarter valued at $147,000. Finally, Renaissance Technologies LLC grew its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.